Greg is a partner at Menlo Ventures where he invests in life science and healthcare, specifically novel therapeutic platforms, digital health and transformative technologies. Greg has led Menlo’s investments in H1 Insights, Ophelia Health, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, Senti Biosciences, Scribe Therapeutics and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals and Cofactor Genomics.Greg has more than 20 years of experience in senior executive and entrepr...read more